Poseida Therapeutics (PSTX)
(Delayed Data from NSDQ)
$2.05 USD
-0.02 (-0.97%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $2.06 +0.01 (0.49%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Poseida Therapeutics, Inc. [PSTX]
Reports for Purchase
Showing records 1 - 20 ( 40 total )
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Inflection Points in Back Half of the Year; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Era of Allogeneic CAR-T on the Horizon; Higher $20 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another Big Pharmas Interest Speaks of the Potential of Poseidas Platforms; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updates from CAR-T Programs Remain On Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Catalysts From Cell Therapy Franchise in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ushering in a New Era of Cell and Gene Therapies; Initiate With Buy and a $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Poseida Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
Dropping Coverage Due to Stryker Acquisition
Provider: Roth Capital Partners, Inc.
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
Distributor Issues Continue, but Macro Positive; HMA Provides ''14 Upside
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
Healthcare - 3Q 2013: Quarterly Medical Technology Trading & Acquisition Update
Provider: Roth Capital Partners, Inc.
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
2Q Inline; Expect Some Continued Choppiness But Still Like Long-Term
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Poseida Therapeutics, Inc.
Industry: Medical - Dental Supplies
Healthcare - 2Q 2013: Quarterly Medical Technology Trading & Acquisition Update
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C